Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Malignant Solid Neoplasm 1

Interventions

Carboplatin 10Cisplatin 7Pemetrexed 6Vincristine 5Nivolumab 5Etoposide 4Topotecan 3Specimen Handling 3Ipilimumab 3Injections 3Doxorubicin 3Talc 2Radiotherapy 2Paclitaxel 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1sintilimab 1ranpirnase 1raltitrexed 1pertuzumab 1pembrolizumab 1onartuzumab 1iniparib 1durvalumab 1dostarlimab 1crofelemer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Asian ginseng × Other solid neoplasm × Clear all
NCT06395441 2026-03-30

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

Mayo Clinic

Phase 3 Recruiting
160 enrolled
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡